Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 1,766

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency

Maschio, Giuseppe, Alberti, Daniele, Janin, Gérard, Locatelli, Francesco, Mann, Johannes F.E., Motolese, Mario, Ponticelli, Claudio, Ritz, Eberhard, Zucchelli, Pietro·1996·New England Journal of Medicine
DOI 10.1056/nejm199604113341502
Open this paper in CoChat — free account

Abstract

BACKGROUND: Drugs that inhibit angiotensin-converting enzyme slow the progression of renal insufficiency in patients with diabetic neuropathy. Whether these drugs have a similar action in patients with other renal diseases is not known. We conducted a study to determine the effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of renal insufficiency in patients with various underlying renal diseases. METHODS: In a three-year trial involving 583 patients with renal insufficiency caused by various disorders, 300 patients received benazepril and 283 received placebo. The underlying diseases included glomerulopathies (in 192 patients), interstitial nephritis (in 105), nephrosclerosis (in 97), polycystic kidney disease (in 64), diabetic nephropathy (in 21), and miscellaneous or unknown disorders (in 104). The severity of renal insufficiency was classified according to the base-line creatinine clearance: 227 patients had mild insufficiency (creatinine clearance, 46 TO 60 ml per minute), and 356 had moderate insufficiency (creatinine clearance, 30 to 45 ml per minute). The primary end point was a doubling of the base-line serum creatine concentration or the need for dialysis. RESULTS: At three years. 31 patients in the benazepril group and 57 in the placebo group had reached the primary end point (P<0.001). In the benazepril group, the reduction in the risk of reaching the end point was 53 percent overall (95 percent confidence interval, 27 to 70 percent), 71 percent (95 percent confidence interval, 21 to 90 percent) among the patients with mild renal insufficiency, and 46 percent (95 percent confidence interval, 12 to 67 percent) among those with moderate renal insufficiency. The reduction in risk was greatest among the male patients; those with glomerular diseases, diabetic nephropathy, or miscellaneous or unknown causes of renal disease; and those with base-line urinary protein excretion above 1 g per 24 hours. Benazepril was not effective in patients with polycystic disease. Diastolic pressure decreased by 3.5 to 5.0 mm Hg in the benazepril group and increased by 0.2 to 1.5 mm Hg in the placebo group. CONCLUSIONS: Benazepril provides protection against the progression of renal insufficiency in patients with various renal diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejm199604113341502

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 22

  1. Zatz R, 1987, Kidney Int Suppl, 20, S123
  2. Cartwright ME, 1988, Lab Invest, 59, 492
  3. 10.1172/JCI112528 · DOI · Paper page
  4. 10.1097/00004872-198806000-00010 · DOI
  5. Ravid M, 1993, Ann Intern Med, 118, 577, 10.7326/0003-4819-118-8-199304150-00001 · DOI · Paper page
  6. 10.1001/jama.271.4.275 · doi:10.1001/jama.271.4.275 · Paper page
  7. 10.1159/000186033 · DOI
  8. 10.1159/000186518 · DOI
  9. Kamper A-L, 1992, Am J Hypertens, 5, 423, 10.1093/ajh/5.7.423 · DOI
  10. Hannedouche T, 1994, BMJ, 309, 833, 10.1136/bmj.309.6958.833 · DOI
  11. 10.1159/000180580 · DOI · Paper page
  12. 10.1016/0140-6736(91)92977-A · DOI
  13. Maschio G, 1987, Kidney Int Suppl, 22, S49
  14. 10.1038/ki.1992.309 · DOI · Paper page
  15. Praga M, 1992, Am J Kidney Dis, 20, 240, 10.1016/S0272-6386(12)80696-2 · DOI
  16. Peterson JC, 1993, J Am Soc Nephrol, 4, 254A
  17. 10.1038/ki.1991.160 · DOI
  18. Gansevoort RT, 1994, J Am Soc Nephrol, 5, 329A
  19. 10.1038/ki.1990.217 · DOI · Paper page
  20. Brown JH, 1994, Nephrol Dial Transplant, 9, 1136, 10.1093/ndt/9.supp.113 · doi:10.1093/ndt/9.supp.113
  21. Raine AEG, 1992, Nephrol Dial Transplant, 7, 7
  22. 10.1056/NEJM199501123320203 · DOI · Paper page

Cited by

Metadata

Authors
Maschio, G., Alberti, D., Janin, G., Locatelli, F., Mann, J. F. E., Motolese, M., Ponticelli, C., Ritz, E., & Zucchelli, P.
Venue
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Published
1996-04-11
Volume
334
Issue
15
Pages
939-945
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
DOI
10.1056/nejm199604113341502
OpenAlex
W2312400976
Cited by
1,766
References
3
FWCI
84.87
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.